- TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million.
- VitaCare is a consumer-focused digital healthcare platform.
- TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023.
- TXMD will also enter into a long-term services agreement to continue to utilize the vitaCare platform.
- The transaction is expected to close by Q2 of 2022.
- VitaCare helps patients understand coverage, identify savings opportunities, and facilitate communication between providers and payors.
- The platform also offers a seamless path for filling a prescription, primarily through its network of third-party pharmacies.
- GoodRx expects the transaction to contribute under 1% to overall revenue and reduce the adjusted EBITDA margin by approximately 2% in 2022.
- Price Action: TXMD shares are up 38% at $0.29, while GDRX shares are down 6.70% at $14.91 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks